I get the whole benefit to science / the world, but can someone please explain the near-term commercial benefit to PYC in this move? Sure, I get they will improve their screening of candidates, etc.... but even though they get $4.5m up-front they have to spend $10m at a time where they are trying to do a lot and every $ is potentially very valuable. Maybe they have some insights into managing/sourcing capital that we haven't been told about yet, but is this the best priority for the limited $'s they have right now? Appreciate any insights.
Ann: AI Driven Drug Discovery Collaboration with Google Cloud, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.020(1.67%) |
Mkt cap ! $688.2M | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.17 | $35.11K | 29.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4126 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 7625 | 1 |
View Market Depth
| Last trade - 12.38pm 18/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |